• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Noom Pivots to Longevity: New Program Combines Microdose GLP-1s with At-Home Biomarker Testing

by Jasmine Pennic 12/15/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Noom has launched Proactive Health Microdose GLP-1Rx, a first-of-its-kind preventive health program designed to intervene before chronic disease takes root. 

– Available to individuals with a BMI of 21 or higher, the offering combines personalized microdoses of GLP-1 medication with comprehensive at-home biomarker testing and Noom’s digital behavior modification platform.

– Priced at $149 per month, the program aims to shift the healthcare paradigm from reactive treatment to proactive longevity by improving metabolic health through a blend of biology, psychology, and technology.

The Pivot to Prevention: Noom bets on “Bridge Medicine” with Microdose GLP-1s and Deep Diagnostics

For the past decade, digital health has largely been a game of reaction—waiting for a diagnosis and then managing the symptoms. Today, Noom signaled a definitive shift in that narrative with the launch of Proactive Health Microdose GLP-1Rx.

Moving beyond its roots in weight loss, the company is positioning itself as a longevity platform. The new offering is not designed solely for those with clinical obesity; it is available to adults with a BMI of 21 or higher—the vast majority of the U.S. population. By pairing low-dose GLP-1 medications with rigorous blood diagnostics and behavioral coaching, Noom aims to intercept metabolic dysfunction before it becomes chronic disease.

“The problem we’re solving is that most Americans are living with suboptimal health — and their blood biomarkers show it,” said Dr. Jeffrey Egler, Chief Medical Officer at Noom. “That eventually manifests as chronic disease.”

The “Microdose” Strategy: Broadening Access to GLP-1s

The headline feature of the program is the use of microdosed GLP-1 medications. Unlike traditional weight-loss prescriptions that ramp up to high doses, this program utilizes smaller, personalized amounts intended to “spark” metabolic improvement without necessarily driving rapid weight loss.

This approach allows Noom to expand eligibility to people who may not qualify for standard obesity treatments but still face cardiometabolic risks. Dr. Egler notes that the starting dose is only 25% of the lowest starting dose in Noom’s other programs, with careful, personalized titration.

“GLP-1s are not a shortcut — they’re the spark,” Egler explained. “They open the door for change, but actively walking through that door is what makes the transformation last. It’s not band-aid medicine, it’s bridge medicine.”

Data You Can See: The Biomarker Engine

While medication provides the physiological assist, data provides the roadmap. The program includes a Noom Biomarkers test kit delivered every four months. Utilizing the Tasso+ device for virtually painless capillary blood collection, the kit tracks 17 advanced markers often overlooked in standard annual physicals, including:

  • ApoB & Lp(a): Emerging predictors for heart disease.
  • HbA1c: The gold standard for tracking blood sugar control and prediabetes.
  • hs-CRP: A critical marker for “silent” inflammation.
  • Hormonal Health: Tracking Testosterone, Estradiol, and DHEA-S for resilience and aging.

“When members understand their bloodwork today, they can strive to improve it tomorrow,” said Noom CEO Geoff Cook. “Within just 16 weeks, they can see for themselves the change in their biomarkers.”

Behavior as the Anchor

Noom is betting that medication alone is insufficient for long-term health—a view supported by data showing high discontinuation rates for GLP-1s. The company’s internal data indicates that members highly engaged with the digital companion app lose 50% more weight than those in the bottom quartile of engagement.

The Noom Longevity Companion app is designed to convert the “food noise” reduction provided by the medication into permanent habit formation. Currently, 40% of active Microdose members use the app daily to log meals, workouts, and stress-reduction techniques.

“Health becomes habit, not effort,” Cook noted. “When identity begins to shift, the door opens to broader transformation.”

The Bottom Line

With 80% of U.S. adults with prediabetes currently undiagnosed, Noom’s strategy addresses a massive gap in the American healthcare system. By democratizing access to advanced diagnostics and “longevity medicine,” the company is attempting to prove that the best way to cure chronic disease is to prevent it entirely.

The Proactive Health Microdose GLP-1Rx Program is available now to eligible members for $149 per month.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Aging Care, GLP-1, Noom

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |